Immunotherapy vs Chemotherapy: The Difference, When Each Is Used and How to Decide

In the infusion chair, the two bags look almost identical: clear fluid, a slow drip, a nurse checking the line. One patient will go home and, within a few weeks, notice hair on the pillow. The neighbor in the next chair may keep every strand yet develop a cough that turns out to be the immune system inflaming the lungs. Same room, same rhythm, profoundly different biology.

That difference is what most people are really asking about when they type immunotherapy vs chemotherapy into a search bar. The internet tends to frame it as old versus new, harsh versus gentle. The evidence is less tidy. Chemotherapy is still the backbone of cure for several cancers. Immunotherapy has changed the outlook for some tumors and done little for others. And in a growing number of situations, oncologists no longer choose between them at all.

This guide walks through how each works, where each earns its place, what the trade-offs are, and the questions that actually move a treatment decision.

What is the difference between immunotherapy and chemotherapy?

The simplest way to hold the distinction: chemotherapy attacks the cancer; immunotherapy recruits your body to do it.

Chemotherapy drugs are cytotoxic, meaning they damage cells that are in the act of dividing. Cancer cells divide relentlessly, so they take the brunt, but so do other fast-turnover tissues such as hair follicles, the lining of the mouth and gut, and the bone marrow that manufactures blood cells. The National Cancer Institute describes this collateral effect as the reason chemotherapy produces its characteristic cluster of side effects.

Immunotherapy does not poison cancer cells at all. It works on the immune system, either by removing the brakes that tumors exploit to hide, by engineering immune cells to hunt specific targets, or by flagging cancer cells so they become visible again. The tumor shrinks because immune cells destroy it, not because a chemical did.

Three practical consequences follow from that mechanistic split:

• Chemotherapy tends to act quickly and predictably but its effect fades once the drug clears. Immunotherapy can be slower to show results yet sometimes produces responses that persist long after treatment stops.
• Chemotherapy works against a broad range of cancers because almost all tumors divide. Immunotherapy works well only when the immune system can recognize the tumor, which varies enormously by cancer type and by individual.
• Side effects differ in kind, not just in degree, which shapes who is a good candidate for each.

Everything else in this article builds on those three ideas.

How does chemotherapy actually work inside the body?

Picture a cell copying its DNA before it splits in two. That copying step is where most chemotherapy drugs strike. Some damage the DNA strands directly, some jam the machinery that unwinds and duplicates them, and others sabotage the scaffolding a cell needs to physically pull apart. A cell caught mid-division with broken DNA usually triggers its own self-destruct program.

Because different drugs hit different stages of the cycle, oncologists frequently combine two or three. A tumor that survives one mechanism may be caught by another, and using lower amounts of several agents can be gentler than a large amount of one.

Timing matters as much as chemistry. Chemotherapy is almost always given in cycles: a day or several days of treatment followed by a rest period, commonly stretching each cycle over two to four weeks, according to the Mayo Clinic. The rest lets healthy tissues recover, particularly bone marrow, while cancer cells, which repair damage less efficiently, fall further behind with each round.

Delivery varies too. Many regimens are intravenous, some are tablets or capsules taken at home, and a few are injected into specific spaces such as the fluid around the spinal cord or the abdominal cavity when a cancer is concentrated there.

The elegance of chemotherapy is also its limitation. It cannot tell a rapidly dividing cancer cell from a rapidly dividing hair or gut cell. That is not a flaw in how it is prescribed; it is written into the mechanism itself.

How does immunotherapy work, and why is it not one thing?

Immunotherapy is an umbrella, not a single treatment, and lumping every type together causes real confusion. The National Cancer Institute groups the main approaches like this:

• Immune checkpoint inhibitors. T cells carry molecular brakes, called checkpoints, that stop them attacking healthy tissue. Many tumors switch those brakes on to shut down the immune response. Checkpoint inhibitors block that interaction so T cells can engage. These are the immunotherapies most people have heard about and the ones most often compared with chemotherapy.
• T-cell transfer therapies. A patient’s own immune cells are collected, expanded or genetically modified in a lab to target the cancer, then returned by infusion. CAR T-cell therapy belongs here and is used mainly in certain blood cancers.
• Monoclonal antibodies. Lab-made proteins that attach to specific markers on cancer cells, either marking them for immune destruction or blocking growth signals.
• Cancer vaccines and immune system modulators. Agents that prime or generally boost immune activity.

The mechanism explains the timeline. Chemotherapy starts killing cells within hours. Immunotherapy has to wake, expand and direct an immune response, which can take weeks. Scans taken early sometimes even show a tumor looking larger because immune cells have flooded into it, a pattern oncologists call pseudoprogression.

The mechanism also explains the ceiling. If a tumor carries few abnormalities the immune system can recognize, or has walled itself off from immune cells, releasing the brakes accomplishes little. This is why biomarker testing sits at the center of any immunotherapy decision.

Why not use immunotherapy instead of chemotherapy for everyone?

It is a fair question, and the honest answer has four parts.

First, immunotherapy only works when the immune system can see the cancer. Tumors with many mutations, such as melanoma or lung cancers linked to smoking, generate abnormal proteins that look foreign. Others, including many pancreatic, prostate and some breast cancers, are immunologically quiet. For those, checkpoint inhibitors alone have shown limited benefit in trials, and chemotherapy or other approaches remain more reliable.

Second, some cancers are already cured by chemotherapy at high rates. Testicular cancer, many childhood leukemias and Hodgkin lymphoma are examples where established chemotherapy-based regimens deliver outcomes that any newer treatment must match before it can replace them. Swapping in an unproven alternative would be a step backward.

Third, speed. A patient with a tumor pressing on an airway or a rapidly rising blood cancer needs shrinkage within days. Immunotherapy usually cannot deliver that; chemotherapy often can.

Fourth, immunotherapy is not risk-free. Autoimmune reactions can affect the lungs, liver, gut, thyroid, pituitary or heart. For people with pre-existing autoimmune disease or an organ transplant, these risks may outweigh the benefit.

The winning question is not ‘which is better’ but ‘which is better for this cancer, with this biology, in this person.’ Increasingly the answer is neither alone, which is why combination regimens have become standard in several cancers.

When is chemotherapy still the better choice?

Chemotherapy remains the default, or a required partner, in more settings than headlines suggest. The clearest scenarios:

• Curative treatment of chemosensitive cancers. Certain lymphomas, leukemias, germ cell tumors and pediatric cancers are treated with intent to cure using chemotherapy-based protocols refined over decades.
• Before or after surgery. Neoadjuvant chemotherapy shrinks tumors to make an operation feasible or less extensive; adjuvant chemotherapy mops up microscopic cells left behind. In breast, colon and bladder cancers, this is where chemotherapy earns much of its survival benefit.
• Alongside radiation. Some drugs make cancer cells more vulnerable to radiation, a strategy used in head and neck, cervical, rectal and some lung cancers.
• Immunologically cold tumors. Where biomarker testing shows low likelihood of immune response, chemotherapy or targeted therapy is generally preferred.
• Urgent debulking. When symptoms from tumor bulk are dangerous, chemotherapy’s rapid action matters.

There is also a quieter reason: familiarity. Oncologists know the side-effect timelines of standard chemotherapy almost to the day, which allows precise supportive care. Anti-nausea strategies, growth-factor support for blood counts and scalp cooling to reduce hair loss have all made modern chemotherapy far more manageable than the version most people picture.

None of this means chemotherapy is pleasant. It means that for many cancers it is still the treatment with the strongest evidence of extending life or achieving cure, and a good decision starts from that evidence rather than from the age of the technology.

When is immunotherapy the first choice?

Immunotherapy moved to the front line in a specific set of situations, and the common thread is a tumor the immune system can recognize.

Melanoma was the proving ground. Advanced melanoma responded poorly to chemotherapy for decades; checkpoint inhibitors changed that, and they are now central to treatment, including after surgery to lower recurrence risk in higher-stage disease.

Non-small cell lung cancer is the second major arena. Tumors are routinely tested for a protein called PD-L1. When expression is high and no targetable mutation is present, immunotherapy alone may be used first; when expression is lower, it is commonly combined with chemotherapy. The test result, not a preference for one modality, drives the choice.

Cancers with mismatch repair deficiency or high microsatellite instability, features found in a minority of colorectal, endometrial and other tumors, accumulate so many mutations that they are unusually visible to T cells. Checkpoint inhibitors are used across tumor types when this signature is present, one of the first treatment approvals in oncology defined by biology rather than organ.

Kidney cancer, bladder cancer, head and neck cancer, some liver and stomach cancers, Hodgkin lymphoma and certain skin cancers round out the list where immunotherapy is used routinely, frequently in combination.

Notice the pattern. Immunotherapy is first choice where trials showed it beats or adds to the previous standard, in patients selected by a biomarker. It is not a general upgrade. If a search result promises otherwise, treat it with caution.

Can you have chemotherapy and immunotherapy together?

Yes, and in several cancers this is now the standard rather than the exception. The logic is more than additive.

Chemotherapy kills cancer cells, and dying cells spill their contents. Those fragments, including abnormal proteins, are picked up by immune sentinel cells and presented to T cells, effectively teaching the immune system what the tumor looks like. Some chemotherapy drugs also deplete regulatory cells that dampen immune responses. Given together, chemotherapy can prime the immune system while immunotherapy releases the brakes, an approach sometimes described as turning a cold tumor warmer.

Clinical trials in lung, triple-negative breast, head and neck, stomach and esophageal cancers have shown the combination outperforms chemotherapy alone in selected patients, which is why it appears in major guidelines for those diseases.

Combining treatments does mean combining side-effect profiles. A person receiving both may experience chemotherapy’s fatigue and blood-count dips alongside the possibility of immune-related inflammation. Care teams monitor for both, and the schedule is typically arranged so that infusions happen on the same day in a single visit.

Sequencing is another form of combination. Immunotherapy may follow chemotherapy and radiation as maintenance in some lung cancers, or be given before surgery to shrink tumors in others. The order is chosen from trial evidence for that specific cancer and stage.

The practical takeaway for readers: if your oncologist proposes both, that is not indecision. It usually reflects the best-supported regimen for your particular diagnosis.

Immunotherapy vs chemotherapy side effects: what actually differs?

Side effects follow mechanism. Chemotherapy harms dividing cells, so its effects cluster in fast-renewing tissues and arrive on a predictable schedule tied to each cycle. Immunotherapy stirs the immune system, so its effects look like autoimmune disease, can appear in almost any organ, and follow no set calendar.

Feature	Chemotherapy	Immunotherapy (checkpoint inhibitors)
Underlying cause	Damage to fast-dividing healthy cells	Immune system attacking healthy tissue
Common effects	Nausea, fatigue, hair loss, mouth sores, low blood counts, neuropathy	Fatigue, rash, itching, diarrhea, joint pain, thyroid changes
Serious effects	Infection from low white cells, bleeding, heart or kidney toxicity with some drugs	Colitis, pneumonitis, hepatitis, hormone gland inflammation, myocarditis
Timing	Predictable, tied to cycle days	Any time, including months after stopping
Reversibility	Mostly resolves after treatment; some neuropathy persists	Usually manageable; some hormone effects are permanent
Main risk-management tool	Dose adjustment, supportive drugs, growth factors	Early recognition, immune-suppressing treatment, pausing therapy

Two nuances get lost in simple comparisons. Chemotherapy side effects are often more frequent, yet the most severe immunotherapy reactions can be harder to predict and occasionally irreversible, such as when the thyroid or adrenal glands stop working. The National Cancer Institute notes that immune-related effects can begin weeks or months into treatment or even after it ends, which is why patients are asked to report new symptoms indefinitely rather than only on infusion weeks.

Neither profile is universally milder. The better question is which set of risks is more acceptable for a given person, and that depends on their other health conditions.

Do you lose your hair on immunotherapy?

Usually not. Hair loss is one of the sharpest practical differences between the two approaches, and it comes straight from the mechanism.

Hair follicles are among the fastest-dividing structures in the body, which makes them a bystander casualty of many chemotherapy drugs. The Mayo Clinic notes that chemotherapy-related hair loss typically begins two to four weeks after treatment starts and that hair usually begins regrowing within three to six months of finishing, sometimes with a temporary change in texture or color. Not every chemotherapy regimen causes it; some produce only thinning, and scalp cooling during infusions can reduce loss for certain drugs.

Checkpoint inhibitors do not target dividing cells, so they do not cause hair loss in this way. A small number of people develop immune-mediated hair changes, such as patchy loss resembling alopecia areata, or whitening of hair and skin as immune cells attack pigment cells, a phenomenon seen most in melanoma treatment. These are uncommon and are considered immune side effects rather than the near-universal shedding associated with strong chemotherapy.

When chemotherapy and immunotherapy are given together, the chemotherapy component determines whether hair falls out.

Hair matters more than it is sometimes given credit for. It is the visible marker of illness, the thing colleagues and children notice. If preserving hair is a priority for you, say so during treatment planning. It may not change the recommendation, but it can shape supportive care, and your team should know what you value.

What are the disadvantages of immunotherapy?

Enthusiasm for immunotherapy is deserved, and it is also selectively reported. The drawbacks are real and worth stating plainly.

It does not work for most people with most cancers. Response depends on the tumor being immunologically visible. Many common cancers respond rarely or not at all to checkpoint inhibitors alone, and even in responsive cancers a majority of patients may not benefit. Biomarker tests improve the odds but do not guarantee a response.

Immune side effects are unpredictable. Because they can strike any organ and appear at any time, they require constant vigilance. Inflammation of the lungs, bowel, liver or heart can be life-threatening if missed. Some hormone-gland damage is permanent and requires lifelong replacement.

It can be slow, and scans can mislead. Pseudoprogression, where a tumor appears larger on early imaging because of immune infiltration, complicates decisions about whether treatment is working.

Not everyone is eligible. Active autoimmune disease, organ transplantation and certain other conditions can make immunotherapy unsafe or unadvisable.

Cost and access. Immunotherapy is among the most expensive treatments in medicine. Health-economic analyses consistently flag this, and access varies widely between health systems and insurance arrangements.

Duration and logistics. Treatment often continues for many months to two years, involving repeated infusions and monitoring.

None of these negate immunotherapy’s achievements. They explain why it is prescribed on evidence and biology rather than offered to everyone, and why an honest conversation about likelihood of benefit belongs at the start of treatment, not the end.

Can stage 4 cancer be cured with immunotherapy?

This is perhaps the most searched and most delicate question, so it deserves a careful answer.

Stage 4 means the cancer has spread to distant sites. For most solid tumors, treatment at this stage has historically aimed to control disease and extend life rather than eliminate it. Immunotherapy has shifted that picture for some cancers, not by guaranteeing cure but by producing, in a subset of patients, responses that last for years after treatment ends. Long-term follow-up of melanoma and lung cancer trials shows a proportion of people alive and disease-free well beyond what earlier treatments achieved, and some oncologists cautiously use the phrase durable remission for these cases.

The honesty required here is twofold. The subset is a minority, and it is concentrated in cancers with high immune visibility. For many stage 4 cancers, immunotherapy adds months of control rather than long-term freedom from disease, and for others it offers little.

Chemotherapy, by comparison, rarely produces lasting remission in metastatic solid tumors, though it can in certain blood cancers and germ cell tumors even at advanced stages.

What this means for a person facing stage 4 disease: ask your oncologist what the realistic goals of treatment are for your specific cancer and biomarker profile. The words to listen for are control, remission and durable, and what each would look like for you. Beware any source, online or otherwise, promising that immunotherapy cures stage 4 cancer as a general statement. The evidence supports hope in specific settings, not a universal claim.

How long does each treatment take, and how do you know it is working?

Timelines differ in ways that affect daily life.

Chemotherapy for curative or adjuvant purposes commonly runs a fixed course, often three to six months, delivered in cycles of two to four weeks each, according to the Mayo Clinic. Metastatic chemotherapy may continue as long as it controls the cancer and side effects remain tolerable, with planned breaks.

Immunotherapy schedules vary by agent; the National Cancer Institute notes it may be given every few weeks, in cycles, or on a fixed schedule for a set period, frequently one to two years in the adjuvant and metastatic settings. Individual infusions are usually shorter than many chemotherapy sessions because no pre-medication for nausea is required.

Assessing response is where the two diverge most. With chemotherapy, a scan after two or three cycles typically tells the story: shrinkage suggests benefit, growth prompts a change. With immunotherapy, early scans are read more cautiously. Because immune cells can infiltrate a tumor and make it appear larger before it shrinks, oncologists may repeat imaging after several more weeks before concluding that treatment has failed, provided the patient is clinically well.

Blood tests also play different roles. Chemotherapy monitoring focuses on blood counts, kidney and liver function ahead of each dose. Immunotherapy monitoring adds thyroid, adrenal and pituitary hormone checks, because inflammation of these glands is a recognized effect.

Neither modality offers a home test for effectiveness. Feeling better is encouraging but not proof; feeling worse may reflect side effects rather than progression. The scan and the conversation that follows remain the arbiters.

How do you and your care team decide between them?

Treatment decisions in oncology are rarely a coin toss between two options. They emerge from a sequence of questions, and knowing that sequence helps you take part in it.

• What exactly is the cancer? Type, subtype and stage narrow the field immediately. Guidelines from bodies such as the WHO, national health services and specialty societies map recommended approaches for each.
• What does the tumor’s biology show? Tests for PD-L1, mismatch repair status, tumor mutational burden and specific driver mutations determine whether immunotherapy, targeted therapy or chemotherapy is most likely to help. Ask whether these tests were done and what they showed.
• What is the goal? Cure, long-term control, symptom relief. The goal changes the acceptable balance of benefit and risk.
• What else is going on in your body? Heart, kidney and liver function, autoimmune history, prior treatments and general fitness all shift the calculation.
• What matters to you? Time in clinic, hair, ability to work, tolerance for uncertainty. These are legitimate inputs, not afterthoughts.

Useful questions to bring to the appointment: What is the evidence for this recommendation in my situation? What would you expect if we chose the other option? What are the most likely side effects, and which ones would you want me to call about immediately? How will we know if it is working, and when?

A second opinion is common and reasonable, particularly for rarer cancers or when the recommendation is uncertain. Good oncologists expect it. The aim is not to find someone who agrees with you but to make sure the decision rests on the widest reading of the evidence.

When to see a doctor: red flags during either treatment

Both chemotherapy and immunotherapy carry risks that can turn serious quickly, and the single most protective habit is calling early rather than waiting for the next appointment. Your care team will give you a contact number for use at any hour. Use it.

Seek care the same day, or go to an emergency department, if you experience any of the following:

• A temperature of 100.4°F (38°C) or higher, chills or shaking, especially during chemotherapy when white blood cell counts may be low. The National Cancer Institute and CDC treat fever during chemotherapy as a potential emergency because infection can progress rapidly.
• New or worsening shortness of breath, persistent cough or chest pain. On immunotherapy these may signal lung or heart inflammation; on chemotherapy they may indicate infection or clot.
• Diarrhea that is severe, contains blood, or comes with abdominal pain, which on immunotherapy can indicate colitis.
• Yellowing of the skin or eyes, dark urine or right-sided abdominal pain, suggesting liver inflammation.
• Severe headache, sudden vision changes, extreme fatigue, dizziness on standing or confusion, which may reflect hormone gland inflammation or low blood pressure.
• Unusual bleeding or bruising, or a widespread rash with blistering or peeling.
• Inability to keep fluids down for more than a day.

Report milder symptoms too, such as new itching, mild diarrhea, joint aches or a change in energy, at your next contact. Immune side effects caught early are far easier to control, and small chemotherapy problems are simpler to fix than large ones. Continue reporting new symptoms even after immunotherapy has ended, because immune-related effects can emerge later.

Frequently asked questions

Is immunotherapy better than chemotherapy?

Neither is better across the board. Immunotherapy outperforms chemotherapy in specific cancers with immune-visible biology, such as melanoma and some lung cancers selected by biomarker tests, while chemotherapy remains superior or essential for many others, including several that it can cure. In a growing number of situations the two are combined. The right comparison is always for a particular cancer type, stage and person, using the trial evidence for that setting.

Why not use immunotherapy instead of chemotherapy?

Because immunotherapy only works when the immune system can recognize the cancer, and many tumors are immunologically quiet. Chemotherapy also acts faster, which matters when a tumor is causing urgent symptoms, and it already cures certain cancers at high rates. Immunotherapy carries its own serious risks, including inflammation of the lungs, bowel and hormone glands, and is unsuitable for some people with autoimmune conditions or transplants.

What are the disadvantages of immunotherapy?

The main drawbacks are that most people with most cancers do not respond to it alone, its side effects are unpredictable and can strike any organ at any time, some hormone damage is permanent, early scans can be misleading, and treatment is expensive and often continues for many months. People with active autoimmune disease or an organ transplant may not be eligible. These limits explain why it is prescribed on biomarker evidence rather than offered universally.

Do you lose your hair on immunotherapy?

Usually not. Checkpoint immunotherapy does not target dividing cells, so it does not cause the widespread shedding associated with many chemotherapy drugs. A small number of people develop patchy immune-related hair loss or whitening of hair, most often during melanoma treatment. When immunotherapy is combined with chemotherapy, the chemotherapy component determines whether hair falls out, typically beginning two to four weeks into treatment according to the Mayo Clinic.

Can stage 4 cancer be cured with immunotherapy?

In a minority of people with certain cancers, particularly melanoma and some lung cancers, immunotherapy has produced remissions lasting years after treatment stopped, which some oncologists describe as durable remission. For many other stage 4 cancers it extends control by months rather than eliminating disease, and for some it offers little benefit. Ask your oncologist what realistic goals look like for your specific cancer and biomarker results rather than relying on general claims.

Can chemotherapy and immunotherapy be given at the same time?

Yes. Combination regimens are standard in several cancers, including certain lung, head and neck, stomach and triple-negative breast cancers. Chemotherapy kills tumor cells, releasing fragments that help the immune system recognize the cancer, while immunotherapy releases the brakes on T cells. Infusions are usually scheduled on the same visit. Side effects of both types can occur, so monitoring covers blood counts as well as signs of immune inflammation.

How quickly does immunotherapy work compared with chemotherapy?

Chemotherapy begins damaging cancer cells within hours and shrinkage is often visible on scans after two or three cycles. Immunotherapy must first activate and expand an immune response, so benefit may take weeks or months to appear, and early scans can show apparent growth from immune cell infiltration, known as pseudoprogression. Oncologists therefore often wait for confirmatory imaging before judging immunotherapy a failure, provided the patient is clinically stable.

Which has worse side effects, immunotherapy or chemotherapy?

They differ in kind more than in severity. Chemotherapy side effects such as nausea, fatigue, hair loss and low blood counts are more frequent and follow a predictable cycle-based pattern. Immunotherapy side effects are less common overall but resemble autoimmune disease, can affect nearly any organ, may appear at any time including after treatment ends, and are occasionally irreversible. Which profile is more acceptable depends on a person’s other health conditions.

What tests decide whether immunotherapy will work?

Tumor tissue is commonly tested for PD-L1 protein expression, mismatch repair deficiency or high microsatellite instability, and sometimes tumor mutational burden. These markers estimate how visible the cancer is to the immune system. Tests for specific driver mutations are also run, because when a targetable mutation is present, targeted therapy may be preferred over immunotherapy. None of these tests guarantees a response; they shift the probability and guide the recommendation.

When should I call my care team during treatment?

Call the same day for a temperature of 100.4°F (38°C) or higher, new shortness of breath or chest pain, severe or bloody diarrhea, yellowing skin, severe headache, confusion, unusual bleeding or an inability to keep fluids down. Report milder new symptoms such as rash, mild diarrhea or joint pain at your next contact. After immunotherapy, continue reporting new symptoms even months later, since immune-related effects can emerge after treatment has ended.

This article is for general information only and is not a substitute for professional medical advice. Please consult a qualified doctor about your individual situation.